Form 10-K

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nextdoor, Snowflake, Chemours, and Evolv and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 30, 2024
Transport, Form 10-K, P.C, Audit committee, Risk, Air conditioning, Electronics, Snowflake Inc., ARPU, Annual report, Ethics, Internet, News, Controller, Acquisition, Refrigeration, IPO, Networking hardware, Senior, SNOW, Adjustment, Growth, CFO, Weapon, COVID-19, School, Complaint, Plastic, Cryptocurrency

On this news, the price of Nextdoor Class A common stock declined approximately 14%.

Key Points: 
  • On this news, the price of Nextdoor Class A common stock declined approximately 14%.
  • On this news, the price of Nextdoor Class A common stock fell approximately 11%, further damaging investors.
  • which lowered credit consumption.” On this news, the price of Snowflake Class A common stock fell nearly 28% over several trading sessions, damaging investors.
  • For more information on the Evolv class action go to: https://bespc.com/cases/EVLV

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

C-Bond Systems to File its Form 10-K on April 1, 2024, and Hold Conference Call to Discuss its Financial Results on April 3, 2024

Retrieved on: 
Friday, March 29, 2024
SAN, Glass, OTC, Form 10-K, Safety

SAN ANTONIO, March 29, 2024 (GLOBE NEWSWIRE) -- C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a developer and marketer of glass strengthening solutions for enhanced safety, announced today that it will file its Form 10-K on April 1, 2024, and issue a press release on April 2, 2024 with its financial results.

Key Points: 
  • SAN ANTONIO, March 29, 2024 (GLOBE NEWSWIRE) -- C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a developer and marketer of glass strengthening solutions for enhanced safety, announced today that it will file its Form 10-K on April 1, 2024, and issue a press release on April 2, 2024 with its financial results.
  • The Company will hold a conference call at 9:30 am ET on April 3, 2024, to discuss those results in more detail and hold a question-and-answer session.
  • The Company will also review its preliminary outlook for its financial results for the first quarter ended March 31, 2024, for which the Company previously stated it expects to report revenues of more than $1 million.
  • To access the live call, please dial 832-917-1510 and enter access code 388794.

AGBA Announces Fourth Quarter 2023 Earnings, Amid Challenging Macro Environment.

Retrieved on: 
Thursday, March 28, 2024
GBA, Growth, Platform, Form 10-K, Security (finance), Insurance, Chinese New Year, Film industry

HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for the fourth quarter of 2023.

Key Points: 
  • HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for the fourth quarter of 2023.
  • The Company generated $48.9 million in commissions from its Distribution Business during the fourth quarter of 2023, which is double the figure generated during the same period in 2022.
  • AGBA has thrived despite macroeconomic challenges, adapting its business model and positioning itself for continued growth.
  • For more details, please refer to the company’s report on Form 10-K filed with the Securities and Exchange Commission on 28 March 2024.

GigaCloud Technology Inc Files Annual Report on Form 10-K for Fiscal Year 2023

Retrieved on: 
Wednesday, March 27, 2024
GCT, Annual report, Form 10-K

EL MONTE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise, today announced that on March 27, 2024, the Company filed its annual report on Form 10-K for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”).

Key Points: 
  • EL MONTE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise, today announced that on March 27, 2024, the Company filed its annual report on Form 10-K for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”).

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Finkelstein, Arrhythmia, Stroke, Annual report, Certification, Myocardial infarction, BCDA, Partnership, Patient, The Study, Morph, Mortality, Form 10-K, Security (finance), Death, Heart transplantation, Quality of life, Doctor of Philosophy, Heart failure, Therapy, Heart, Safety, Data, Medicare, FDA, Helix, Arrest, Hospital, Pharmaceutical industry

The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

Key Points: 
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.
  • The Company anticipates completing follow-up in the trial and preparing this dataset on 115 randomized patients enrolled with a minimum of one-year follow-up for final lock in the fourth quarter of 2024.
  • BioCardia has had discussions on partnering its CardiAMP therapy for other clinical indications and continues to explore partnerships worldwide.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call.

Trust Stamp Provides a Business Report and Financial Results for the Year Ended December 31, 2023

Retrieved on: 
Wednesday, March 27, 2024
Common stock, Negotiation, Comment, Longevity, Software as a service, Growth, Partnership, Independent, Research, Form 10-K, Security (finance), ICE, Trust, Investment, FIS, Cryptocurrency

Atlanta, GA, March 27, 2024 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity Company ™ providing AI-powered trust and identity services used globally across multiple sectors, announced financial results and provided a business update for year ended December 31, 2023.

Key Points: 
  • Atlanta, GA, March 27, 2024 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity Company ™ providing AI-powered trust and identity services used globally across multiple sectors, announced financial results and provided a business update for year ended December 31, 2023.
  • Trust Stamp Chief Executive Officer, Gareth N. Genner commented, “I am pleased to report our progress for the year ended December 31, 2023.
  • The relationship with our long-term customers remains very strong and we anticipate continued long-term growth in the revenue derived from those relationships.
  • This resulted in a basic and net loss per share of $1.07 for year ended December 31, 2023 compared to $2.55 for year ended December 31, 2022.

NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday

Retrieved on: 
Wednesday, March 27, 2024
Good, International, Webcast, Gel, OTC, Form 10-K, Health

The Company intends to file its Form 10-K with the SEC and issue a press release prior to the start of the call.

Key Points: 
  • The Company intends to file its Form 10-K with the SEC and issue a press release prior to the start of the call.
  • Adam Levy, CEO of NEXGEL, commented, “In light of the stock markets being closed to observe the Good Friday holiday, we are moving the reporting of our 2023 financial results to Monday morning before the market open.
  • Participants must use the following code to access the replay of the call: 1155204.
  • An archived version of the webcast will also be available for 90 days.

Odysight.ai Announces 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, Annual report, Paris Air Show, CBM, Aviation, G&A, Form 10-K, PDM, OTCQB, Marketing

OMER, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announced financial results for the year ended December 31, 2023 and the filing of its annual report on Form 10-K for such year with the U.S. Securities and Exchange Commission. As of December 31, 2023, Odysight.ai had $17.0 million of cash and short-term deposits on its balance sheet.

Key Points: 
  • As of December 31, 2023, Odysight.ai had $17.0 million of cash and short-term deposits on its balance sheet.
  • Revenues for the year ended December 31, 2023 were $3.0 million, compared to $0.7 million for the year ended December 31, 2022.
  • Research and development (R&D) expenses for the year ended December 31, 2023 were $5.6 million, compared to $4.2 million for the year ended December 31, 2022.
  • Sales and marketing (S&M) expenses for the year ended December 31, 2023 were $1.1 million, compared to $0.7 million for the year ended December 31, 2022.

R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report

Retrieved on: 
Wednesday, March 27, 2024
Health, Annual report, Culture, Organization, Intermountain, Human Rights Campaign, ESG, Patient, RCM, Form 10-K, Bank statement, Social, Reliability-centered maintenance, Tree, Workplace, U.N, Management

MURRAY, Utah, March 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, has released its 2023 Environmental, Social and Governance (ESG) report .

Key Points: 
  • MURRAY, Utah, March 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, has released its 2023 Environmental, Social and Governance (ESG) report .
  • The report details the company’s commitment to improving access to healthcare, bringing responsible global citizenship to life through its ESG program.
  • R1 does not undertake to update its forward-looking statements except to the extent required by applicable law.
  • All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements.